Stereotactic Body Radiotherapy Combined With Cadonilimab for Advanced Refractory Malignant Solid Tumors

NCT05915481 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

UNKNOWN

Status

60

Enrollment

OTHER

Sponsor class

Conditions

Advanced Solid Tumor
Stereotactic Body Radiotherapy
Immune Checkpoint Inhibitor
Safety
Efficacy

Interventions

DRUG: Cadonilimab
RADIATION: Stereotactic body radiotherapy

Sponsor

Peking University Third Hospital